Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Insulin human/Insuman Comb 25 (HR1799)Drug: Insulin human/Novolin® 30R
- First Posted Date
- 2011-05-13
- Last Posted Date
- 2013-02-27
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 485
- Registration Number
- NCT01353469
- Locations
- 🇨🇳
Investigational Site Number 156029, Suzhou, China
🇨🇳Investigational Site Number 156010, Beijing, China
🇨🇳Investigational Site Number 156006, Chongqing, China
Repeated Dosing Study With a New Insulin Glargine Formulation and Lantus® in Patients With Type 1 Diabetes Mellitus
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Drug: Insulin glargine HOE901
- First Posted Date
- 2011-05-09
- Last Posted Date
- 2011-06-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 30
- Registration Number
- NCT01349855
- Locations
- 🇩🇪
Investigational site number 276001, Neuss, Germany
Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: 75% insulin lispro protamine suspension and 25 % insulin lispro injection
- First Posted Date
- 2011-04-18
- Last Posted Date
- 2011-04-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 212
- Registration Number
- NCT01336751
- Locations
- 🇺🇸
Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States
Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel
- Conditions
- Ovarian Cancer Recurrent
- Interventions
- First Posted Date
- 2011-04-11
- Last Posted Date
- 2015-12-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 154
- Registration Number
- NCT01332656
- Locations
- 🇺🇸
Investigational Site Number 840002, Boston, Massachusetts, United States
🇨🇿Investigational Site Number 203004, Zlin, Czech Republic
🇷🇺Investigational Site Number 643003, Moscow, Russian Federation
Comparison of the Safety and Pharmacokinetics of Two SAR153191 (REGN88) Drug Products in Rheumatoid Arthritis Patients
- First Posted Date
- 2011-04-04
- Last Posted Date
- 2011-10-24
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 32
- Registration Number
- NCT01328522
- Locations
- 🇺🇸
Investigational Site Number 840001, Ocala, Florida, United States
🇺🇸Investigational Site Number 840004, Duncansville, Pennsylvania, United States
🇺🇸Investigational Site Number 840002, Dallas, Texas, United States
Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer
- First Posted Date
- 2011-03-29
- Last Posted Date
- 2015-01-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 48
- Registration Number
- NCT01324583
- Locations
- 🇯🇵
Investigational Site Number 392008, Maebashi-Shi, Japan
🇯🇵Investigational Site Number 392015, Nagoya-Shi, Japan
🇯🇵Investigational Site Number 392003, Sunto-Gun, Japan
Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma
- Conditions
- Asthma
- Interventions
- Drug: Placebo (for Dupilumab)Drug: Fluticasone/Salmeterol combination therapy
- First Posted Date
- 2011-03-11
- Last Posted Date
- 2017-06-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 104
- Registration Number
- NCT01312961
- Locations
- 🇺🇸
Investigational Site Number 840003, Minneapolis, Minnesota, United States
🇺🇸Investigational Site Number 840006, Saint Louis, Missouri, United States
🇺🇸Investigational Site Number 840047, Anaheim, California, United States
Study of Adacel® Vaccine Administered to Persons 10 Years of Age
- Conditions
- TetanusPertussisDiphtheria
- First Posted Date
- 2011-03-09
- Last Posted Date
- 2016-04-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1302
- Registration Number
- NCT01311557
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2011-03-04
- Last Posted Date
- 2019-06-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1168
- Registration Number
- NCT01308567
- Locations
- 🇫🇷
Investigational Site Number 250010, Besancon Cedex, France
🇺🇸Investigational Site Number 840035, Jacksonville, Florida, United States
🇧🇾Investigational Site Number 112001, Minsk, Belarus
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2011-03-04
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1200
- Registration Number
- NCT01308580
- Locations
- 🇺🇸
Investigational Site Number 840014, Baltimore, Maryland, United States
🇺🇸Investigational Site Number 840021, Stamford, Connecticut, United States
🇺🇸Investigational Site Number 840020, Akron, Ohio, United States